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ABSTRACT
Background and the purpose of the study: Pentoxifylline (PTX) is a non-specific cytokine 
inhibitor that has been reported to attenuate pain in several animal models and humans. However, 
long-term therapeutic effects of PTX on neuropathic pain in a rat model of chronic constriction 
injury (CCI) are not completely clear. This study was conducted to examine the effect of long-
term administration of PTX on neuropathic pain in rats.
Methods:  Neuropathic pain was induced by sciatic nerve ligation using of CCI model in rats. 
Rats were randomly assigned into sham, CCI-saline treated, and CCI-PTX treated (30 or 60 
mg/kg ip) groups. PTX or saline administered at 30 min before CCI and daily for 14 days post-
CCI. At the days of 3, 7, 11 and 14 following CCI, by using standard methods effects of thermal 
hyperalgesia, thermal and mechanical allodynia in all groups were examined using the standard 
methods.  
Results: The CCI-saline treated group showed a significant increase in mechanical and thermal 
allodynia, and thermal hyperalgesia as compared with the sham group in the tested days.  
Administration of the higher dose of PTX (60 mg/kg/day), but not the lower dose (30 mg/
kg/day) significantly reduced mechanical and thermal allodynia,  as compared with the CCI–
saline treated group on days of 3, 7, 11 and 14  (all P values<0.001). Also, both doses of PTX 
significantly reduced thermal hyperalgesia as compared with the CCI-saline treated group on 
these days (all P values<0.001).  
Conclusion:  Results  of  this  study  show  that  chronic  administration  of  PTX  reduces  the 
neuropathic pain in a rat model of CCI. Thus, this drug may have a therapeutic application in 
the treatment and management of neuropathic pain in humans.
Keywords: Chronic Constriction Injury (CCI), Thermal hyperalgesia, Thermal and mechanical 
allodynia.
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INTRODUCTION
Neuropathic pain is a persistent pain which induced 
following peripheral or central nervous system 
injuries (1). Hyperalgesia (an increased response to 
normally painful stimuli) and allodynia (a painful 
response to normally harmless stimuli) are abnormal 
sensory signs which are usually observed along 
neuropathic pain (1). These behavioral parameters 
have been often used to study the pharmacology 
and modulation of neuropathic pain (1). In spite of 
many investigations the underlying mechanisms of 
with neuropathic pain and its phatophysiology are 
not completely clear (1-5). 
Recently  several  evidences  suggested  that  pro-
inflammatory  cytokines  such  as  tumor  necrosis 
factor-alpha (TNF-α) and interleukin-1 might be 
involved in the genesis, persistence and severity of 
neuropathic pain (1, 6-8). It has been demonstrated 
that  administration  of  anti-TNF-alpha  and  IL-
1b  monoclonal  antibodies  provided  analgesia  in 
rheumatoid arthritis patients (9). Nowadays, pro-
inflammatory cytokines is a new approach for the 
management of inflammatory and neuropathic pain 
in clinical situations. 
Pentoxifylline  (PTX),  an  inhibitor  of  phospho-
diesterase  and  non-specific  inhibitor  of  cytokine   
(10,  11),  which  inhibits  the  synthesis  of TNF-α, 
interlukine-1  (IL-1),  IL-6,  and  IL-8  (12-14). 
Previous studies have shown beneficial effects of 
PTX  in  dermatitis,  leprosy,  rheumatoid  arthritis, 
cancer (15-17) and cerebral ischemia (18, 19). A 
few  studies  have  demonstrated  that  PTX  is  able 
to attenuate the formalin-induced pain behavior in 
rats (12) and post-operative pain in patients (20). 
Additionally, the anti-hyperalgesic effects of PTX 
in  three  experimental  inflammatory  pain  models 
306have been demonstrated and it is shown that this 
effect  was  associated  with  inhibition  of  TNF-α 
synthesis  (7).  Study  of  Liu  and  his  colleagues 
showed  that  PTX  significantly  decreased 
mechanical and thermal hyperalgesia in rats with 
L5 nerve transection model (13). A recent study 
showed PTX decreased allodynia and hyperalgesia 
considerably on the day of seven after CCI in rat 
and mice (21). 
Taken  together, long-term  therapeutic  effects of 
PTX on neuropathic pain in rat model of CCI is not 
completely clear. Therefore, the aim of this study 
was to examine whether  pre-emptive and repeated 
systemic  administration  of  PTX  for  two  weeks 
could attenuate mechanical and thermal allodynia 
and hyperalgesia in rat model of neuropathic 
pain. 
MATERIAL AND METHODS
Animals and Drug
Adult male Wistar rats (200-250 g) were obtained 
from breeding colony of Semnan University of 
Medical Sciences (SUMS), Semnan, Iran. All rats 
were housed in cages in a 12-h light/dark cycle 
at 22–24◦C, with food and water ad libitum. All 
procedures were conducted in agreement with the 
National Institutes of Health Guide for Care and 
Use of Laboratory Animals.
PTX  was  purchased  from  Fluka  company 
(Germany). The drug was dissolved in physiological 
saline  and  injected  at  doses  of  30  or  60  mg/kg 
(i.p). These doses were selected on the basis of the 
previous pilot studies (14, 18).   
Neuropathic pain model
Chronic constriction injury model was used to 
induce neuropathic pain as it was previously 
described (22). Briefly, under ketamine/xylazine 
(80  mg/kg  and  10  mg/kg,  i.p  respectively) 
anesthesia the left sciatic nerve was exposed 
and  then  four  loss  ligatures  (4/0  cutgoat 
plain) was placed around the nerve with 1mm 
spacing until a brief twitch in the hind limb was 
observed. Afterward, in all animal’s thermal 
hyperalgesia, mechanical and thermal allodynia 
were evaluated on days of  3, 7, 11 and 14 after 
surgery or CCI.     
Experimental protocol 
Forty rat were assigned randomly to four groups 
(each, n=10). Group 1 was sham-operated (surgery 
without  induction  of  CCI).    Group  2  was  the 
control, which received saline (1 ml/kg). Groups 3 
and 4 were treated with PTX at doses of 30 mg/kg 
and 60 mg/kg, respectively.  In all groups, PTX 
or saline was given 30 min before CCI and then 
daily for 14 days post-CCI.  Next, behavioral tests 
including thermal hyperalgesia, mechanical and 
thermal allodynia were performed in each group 
on days of 3, 7, 11 and 14 after surgery or CCI (see 
below). 
Behavioral tests
Mechanical allodynia (Von Frey test)
Mechanical allodynia was measured using a series 
of von Frey filaments (Stoelting, Wood Dale, IL, 
USA), ranging from 2 to 60 g (23). To measure 
mechanical allodynia, each rat was placed in plastic 
cages with wire net floor, were allowed to move 
freely. All animals were allowed to adapt to this 
environment for 5 min before testing.  Afterward, 
the Von Frey filament was applied by gentle increase 
in the strength (2-60 g) to left dorsal surface of the 
hind paw until the rat lifted the paw away (21, 23).   
Three tests were performed at intervals of 5 min 
and the applied force (g) was recorded.
Thermal hyperalgesia 
Thermal  hyperalgesia  was  determined  by  using 
paw withdrawal latencies to radiant heat (Model 
390,  IITC  Life  Science,  INC.). After  adaption  of 
animals to the Plexiglas cage, the movable radiant 
heat source under the glass floor was focused on the 
plantar surface of the hind paw until animal lifted 
the paw away. The paw withdrawal latencies were 
measured for left and right hind paw of each animal 
for three times with intervals of 5 min and a cut-off 
time was set at 20 s to avoid tissue damage. 
Thermal allodynia
Acetone test was used to determine thermal allodynia. 
Rats were placed in plastic cages with a wire-mesh 
floor and afterr adaptation to environment by using 
of syringe filled with acetone, animals were pushed 
to left hind paw until the animal lifted the paw away.   
Three tests were done 5 times at intervals of 3 min.   
Withdraw hind paw was considered as a positive 
response.
Statistical analyses
Data  are  presented  as  mean  ±  SEM.    Thermal 
and mechanical allodynia data were analyzed by 
non-parametric  Kruskal-Wallis  ANOVA  on  ranks 
followed  by  a  Dunn's  test  (SigmaStat  2.0,  Jandel 
Scientific, Erkrath, Germany). Thermal hyperalgesia 
was analyzed by one way analysis of variance 
(ANOVA)  followed  by  Dunnet  test  as  post  hoc 
analysis. Differences were considered significant at 
P<0.05.
RESULTS
Administration  of  PTX  (60  mg/kg)  30  min  before 
CCI and then once a day for 14 days, significantly 
reduced the percent of withdrawal threshold (thermal 
allodynia) and mechanical threshold (mechanical 
allodynia) on days of 3, 7, 11 and 14 after CCI as 
compared with saline-treated CCI group  (Figs. 1, 2A, 
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B, C and D; P<0.001). The lower dose (30 mg/kg), 
of PTX was effective on these measures except on 
the day of 3 after injury (Figs. 1, 2A, B, C and D; 
P>0.05).  
PTX at both doses (30 and 60 mg/kg) significantly 
reduced thermal threshold (thermal hyperalgesia) in 
all days after CCI as compared with control group 
(Fig. 3A, B, C and D; P<0.001). 
DISCUSSION
In this study, a rat model of CCI was used to study 
chronic pain because it mimics clinical condition 
of chronic nerve compression such as spinal root 
irritation by a lumbar disk herniation in humans 
(1).  Strong  mechanical,  thermal  allodynia  and 
thermal hyperalgesia appeared from the third day 
after injury, which is consistent with results of other 
studies (21, 23).  
It was found that chronic application of PTX only 
at the dose of 60mg/kg considerably attenuated both 
thermal and mechanical allodynia. These findings 
are in agreement with results of a previous study 
that demonstrated PTX only at higher doses (50 or 
100 mg/kg) could diminish thermal and mechanical 
hyperalgesia in spinal nerve transaction rat model 
(13). However, findings of this study are in contrast 
with another study that demonstrated systemic 
injection  of  PTX  failed  to  alleviate  mechanical 
allodynia (24).  In the study of Liu and colleagues, 
PTX  was  given  for  7  days  after  L5  spinal  nerve 
transection, while in the present study rats received 
PTX daily for 14 days after injury in CCI model. 
Therefore, part of this discrepancy might be related 
to the differences in the duration of PTX injection 
and/or model nerve injury which was applied.
Other findings of this study is that PTX at both 
low and high doses noticeably decreased thermal 
hyperalgesia on days of  3, 7, 11 and 14 after 
injury, whereas the low dose of PTX did not have 
any effect on thermal and mechanical allodynia. 
Fig. 1A Fig. 1B
Fig. 1C Fig. 1D
Figure 1. . Effects of pre-emptive and repeated administration of pentoxifylline (PTX) at doses of 30 mg/kg (PTX-30) and 60 mg/kg 
(PTX-60) on the percent of withdrawal threshold (thermal allodynia, Acetone  test)  on days  of 3(A), 7(B),11(C) and 14(D) after injury in 
rat. The data are presented as the Mean±SEM. #P<0.001 versus Sham group; *P<0.001 versus saline-treated chronic constriction injury 
(CCI). 
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Fig. 2A Fig. 2B
Fig. 2C Fig. 2D
Figure 2. Effects  of pre-emptive and repeated administration of pentoxifylline (PTX) at doses of 30 mg/kg (PTX-30) and 60 mg/kg 
(PTX-60) on mechanical threshold(gram) (Von Fery test) on days of  3(A), 7(B),11(C) and 14(D) after chronic constriction injury (CCI)     
in rat. The data are presented as the Mean±SEM. #P<0.001 versus Sham group; *P<0.001 versus saline-treated CCI group.
This  inconsistency  in  response  to  PTX  is  not 
clear, but may be related to the difference in 
pathophysiology of thermal hyperalgesia and 
allodynia (25, 26).
Several studies have reported that pro-inflammatory 
cytokines  such  as  tumor  necrosis  factor  (TNF-
α), interleukin-1 (IL-1) and nuclear factor-kappa 
B  (NF-κB)  may  contribute  to  pathogenesis  of 
neuropathic pain, with peripheral and or central 
nervous system mechanisms (8, 13, 27, 28). It has 
been shown that an inhibition of the activation 
of NF-κB reduced hyperalgesia in inflammatory 
and neuropathic pain models of rats (29). Another 
study  showed  that  PTX  dose-dependently 
attenuated the development of mechanical and 
thermal hyperalgesia via inhibiting the expression 
of pro-inflammatory cytokines and the activation 
of nuclear factor kappa B in the prefrontal brain in 
spinal nerve transection rat model (13). A number 
of  studies  have  shown  that  PTX  inhibited  the 
synthesis of IL-1 and IL-6 and activation of NF-
κB (7, 12, 13, 30).  Similarly, results of our recent 
study indicated that PTX (60 mg/kg) significantly 
reduces synthesis of TNF-α in ischemic brain in rats 
(14). Thus, it may be suggest that the attenuation 
of behavioral thermal, mechanical and thermal 
hyperalgesia  by  PTX  after  nerve  injury  could 
be due to its inhibitory effect on the production 
of  inflammatory  cytokines.  Further  studies  are 
required to examine this assumption.
In  conclusion,  findings  of  this  study  showed 
that  chronic  administration  of  PTX  reduces  the 
neuropathic pain responses in a rat model of chronic 
constriction injury probably via inhibition of pre- 
inflammatory cytokines. Thus, this drug may have a 
potential therapeutic application in the treatment and 
management of neuropathic pain in humans.
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Fig. 1A Fig. 1B
Fig. 1C Fig. 1D
Figure 3. . Effects of pre-emptive and repeated administration of pentoxifylline (PTX) at doses of 30 mg/kg (PTX-30) and 60 mg/kg 
(PTX-60) on the percent of withdrawal threshold (thermal allodynia, Acetone  test)  on days  of 3(A), 7(B),11(C) and 14(D) after injury in 
rat. The data are presented as the Mean±SEM. #P<0.001 versus Sham group; *P<0.001 versus saline-treated chronic constriction injury 
(CCI). 
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